Crossmark

Performance of the WHOQOL-BREF among Norwegian substance use disorder patients

Crossref DOI link: https://doi.org/10.1186/s12874-019-0690-3

Published Online: 2019-03-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Muller, Ashley Elizabeth http://orcid.org/0000-0001-7819-6697
Skurtveit, Svetlana

Clausen, Thomas
License Information

Text and Data Mining valid from 2019-03-04
More Information

Article History

Received: 15 June 2018

Accepted: 22 February 2019

First Online: 4 March 2019

Authors’ information

: Dr. Muller specializes in assessing the quality of life and other patient-reported outcomes of marginalized populations. Dr. Skurtveit is a pharmacoepidemiologist and works with countries across Europe to identify emerging trends of problematic opioid use. Dr. Clausen leads the Norwegian Centre for Addiction Research and advises the EMCDDA and WHO on issues of substance use and healthy ageing.

: The Norwegian Regional Ethics Committee approved the study (ref: 2012/1131/REK). Written informed consent was obtained from all individual participants prior to inclusion into the study.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.